LAMY reported zero revenue and increasing net losses in its most recent quarter ended February 28, 2026, highlighting severe liquidity constraints including default on a $250,000 convertible note. The company has pivoted significantly from its original educational gaming business centered on the twoplus1® financial literacy video game to focus primarily on biotechnology innovation via its acquisition of Exousia AI, a clinical-stage oncology-focused firm. This strategic shift introduces new operational complexities and funding demands as LAMY attempts to balance early-stage biotech R&D expenses against its nascent subscription gaming model. The continuation of operations depends critically on successful capital raises in an uncertain financing environment.